CO6300953A2 - Antagonistas del receptor mineralcorticoide y metodos de uso - Google Patents

Antagonistas del receptor mineralcorticoide y metodos de uso

Info

Publication number
CO6300953A2
CO6300953A2 CO10072532A CO10072532A CO6300953A2 CO 6300953 A2 CO6300953 A2 CO 6300953A2 CO 10072532 A CO10072532 A CO 10072532A CO 10072532 A CO10072532 A CO 10072532A CO 6300953 A2 CO6300953 A2 CO 6300953A2
Authority
CO
Colombia
Prior art keywords
methods
compound
formula
mineralcorticoid
pharmaceutically acceptable
Prior art date
Application number
CO10072532A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300953(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6300953A2 publication Critical patent/CO6300953A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de Fórmula (I):o una sal del mismo farmacéuticamente aceptable; composiciones farmacéuticas que comprende un compuesto de Fórmula (I) en combinación con un portador, diluyente o excipiente adecuado; y métodos para tratar trastornos fisiológicos, particularmente insuficiencia cardiaca congestiva, nefropatía diabética, o enfermedad renal crónica, que comprende administrar un compuesto de Fórmula (I), o una sal del mismo farmacéuticamente aceptable.
CO10072532A 2007-12-19 2010-06-16 Antagonistas del receptor mineralcorticoide y metodos de uso CO6300953A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
CO6300953A2 true CO6300953A2 (es) 2011-07-21

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10072532A CO6300953A2 (es) 2007-12-19 2010-06-16 Antagonistas del receptor mineralcorticoide y metodos de uso

Country Status (34)

Country Link
US (1) US7994164B2 (es)
EP (2) EP2235007B1 (es)
JP (1) JP5562866B2 (es)
KR (1) KR101254382B1 (es)
CN (1) CN101903377B (es)
AR (1) AR069554A1 (es)
AU (1) AU2008343524B2 (es)
BR (1) BRPI0820805A2 (es)
CA (1) CA2710409C (es)
CL (1) CL2008003600A1 (es)
CO (1) CO6300953A2 (es)
DK (1) DK2235007T3 (es)
DO (1) DOP2010000185A (es)
EA (1) EA017668B1 (es)
EC (2) ECSP10010266A (es)
ES (2) ES2459318T3 (es)
GT (1) GT201000179A (es)
HK (1) HK1144284A1 (es)
HR (1) HRP20120916T1 (es)
IL (1) IL206353A (es)
MA (1) MA31910B1 (es)
MX (1) MX2010006911A (es)
MY (1) MY150474A (es)
NZ (1) NZ586300A (es)
PE (1) PE20091057A1 (es)
PL (1) PL2235007T3 (es)
PT (1) PT2235007E (es)
RS (1) RS52594B (es)
SI (1) SI2235007T1 (es)
TN (1) TN2010000292A1 (es)
TW (1) TWI431010B (es)
UA (1) UA100131C2 (es)
WO (1) WO2009085584A1 (es)
ZA (1) ZA201004257B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
BR112017007112A2 (pt) * 2014-11-21 2017-12-26 Lilly Co Eli compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JP7090599B2 (ja) * 2016-09-24 2022-06-24 山東亨利醫藥科技有限責任公司 ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
NZ532827A (en) * 2001-11-21 2007-09-28 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) * 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
KR101107800B1 (ko) 2006-10-31 2012-01-25 화이자 프로덕츠 인코포레이티드 무기질코르티코이드 수용체 길항제로서의 피라졸린 화합물
CN101652142B (zh) 2007-03-29 2013-01-02 Msd欧斯股份有限公司 盐皮质激素受体拮抗剂
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
HRP20120916T1 (hr) 2012-12-31
BRPI0820805A2 (pt) 2015-06-16
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
JP2011507868A (ja) 2011-03-10
IL206353A0 (en) 2010-12-30
TN2010000292A1 (en) 2011-11-11
ECSP10010266A (es) 2010-07-30
ECSP12012048A (es) 2012-08-31
AR069554A1 (es) 2010-02-03
MY150474A (en) 2014-01-30
PE20091057A1 (es) 2009-07-20
GT201000179A (es) 2012-04-16
NZ586300A (en) 2012-06-29
KR101254382B1 (ko) 2013-04-15
TWI431010B (zh) 2014-03-21
EA201070762A1 (ru) 2010-12-30
EA017668B1 (ru) 2013-02-28
PT2235007E (pt) 2013-01-22
AU2008343524A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
SI2235007T1 (sl) 2013-01-31
PL2235007T3 (pl) 2013-03-29
CA2710409C (en) 2012-11-06
DOP2010000185A (es) 2010-09-15
EP2235007B1 (en) 2012-10-31
MA31910B1 (fr) 2010-12-01
CN101903377A (zh) 2010-12-01
JP5562866B2 (ja) 2014-07-30
KR20100082866A (ko) 2010-07-20
TW200930721A (en) 2009-07-16
EP2235007A1 (en) 2010-10-06
UA100131C2 (uk) 2012-11-26
ZA201004257B (en) 2011-11-30
RS52594B (en) 2013-04-30
ES2396605T3 (es) 2013-02-22
CN101903377B (zh) 2014-07-09
CL2008003600A1 (es) 2010-02-19
AU2008343524B2 (en) 2012-03-08
EP2537845B1 (en) 2014-03-19
ES2459318T3 (es) 2014-05-09
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
IL206353A (en) 2014-06-30
HK1144284A1 (en) 2011-02-11
WO2009085584A1 (en) 2009-07-09
EP2537845A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
CO6300953A2 (es) Antagonistas del receptor mineralcorticoide y metodos de uso
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
MX2010004503A (es) Compuesto de oxadiazolidinediona.
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
UY32062A (es) Inhibidores de beta-secretasa
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
CR20210085A (es) Compuestos de 2,6-diaminopiridina
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
DK1919896T3 (da) Aminoarylsulfonamidderivater, som funktionelle 5-HT6-ligander
WO2012163088A3 (zh) 肾病和心脏病的治疗药物及其用途
CR11471A (es) Antagonista del receptor mineralcorticoide y metodos de uso
JO2827B1 (en) Mineralocorticoid receptor antagonists and methods of use
DK1948166T3 (da) Carbazolderivater som funktionelle 5-HT6-ligander
TH111703A (th) มินเนอโรคอร์ติซอยด์ รีเซปเตอร์ แอนทากอนิสท์ และวิธีการใช้

Legal Events

Date Code Title Description
FC Application refused